TIM3 Monoclonal Antibodies for PtdSer Binding Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies face challenges in effectively targeting the inhibitory receptor TIM3, which is associated with T cell exhaustion and dysfunction, leading to reduced efficacy in treating chronic diseases such as cancer.
Innovation Solution
Development of isolated monoclonal antibodies that specifically bind to TIM3, stimulating immune responses, inducing T cell activation, and blocking TIM3-PtdSer binding, while maintaining high affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TIM3-targeting immunotherapies are developed to counteract T cell exhaustion, then immune response efficacy is improved, but challenges in effectively targeting TIM3 reduce treatment success
Solution Approach 1:
The patent segments the TIM3 protein into specific epitopes (linear and conformational) that can be targeted by monoclonal antibodies. By identifying and targeting specific regions of TIM3 rather than the entire protein, the therapy achieves reliable blockade of TIM3 function while simplifying the targeting approach through focused epitope-specific antibody design.
Solution Approach 2:
The patent uses monoclonal antibodies as intermediary molecules that specifically bind to TIM3 and its ligands (such as galectin-9 and phosphatidylserine). These antibodies act as mediators that block the interaction between TIM3 and its ligands, thereby counteracting T cell exhaustion without requiring direct manipulation of the TIM3 protein itself.
2Productivity
If monoclonal antibodies are designed to bind TIM3 with high affinity, then immune response stimulation is improved, but specificity requirements increase development complexity
Solution Approach 1:
The patent applies local quality by designing monoclonal antibodies that target specific epitopes on the TIM3 protein rather than the entire surface. Different antibodies are designed to bind to different local regions (epitopes) of TIM3, including linear epitopes and conformational epitopes, allowing high-affinity binding with precise spatial localization that enhances immune stimulation while maintaining manufacturable specificity.
Solution Approach 2:
The patent utilizes parameter changes by varying the binding characteristics of monoclonal antibodies through selection of different epitopes with distinct properties (linear vs. conformational, different affinity constants). This allows optimization of antibody parameters such as binding affinity and specificity to achieve high productivity in immune response stimulation while managing the precision requirements through systematic parameter selection.
3Ease of operation
If TIM3 ligand binding is blocked to prevent T cell exhaustion, then T cell activation is improved, but blocking multiple ligand interactions increases therapeutic complexity
Solution Approach 1:
The patent achieves universality by developing monoclonal antibodies that can block multiple TIM3-ligand interactions simultaneously. A single antibody can interfere with binding of various ligands (galectin-9, phosphatidylserine, HMGB1) to TIM3, providing multi-functional blockade that simplifies therapeutic operation by using one agent to address multiple exhaustion pathways rather than requiring separate therapies for each ligand.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies enhance antigen-specific T cell responses, increase cytokine production, and promote T cell proliferation, thereby improving the immune response against tumors.
Implementation Method 1
isolated antibodies, such as monoclonal antibodies, in particular human (e.g., monoclonal) antibodies, that specifically bind TIM3
Implementation Method 2
blocking TIM3-PtdSer binding
Data Source
AI summary
Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.